Evidence map›Paper›PMID 40325180›Full record

ArticleGenes and immunity2025

Characterizing the immune landscape of tumor-infiltrating lymphocytes in non-small cell lung cancer.

Jin-Guo Liu, Lin Yu, Xian-Ling Guo, Xue-Min He, Man Li, Ren-Yuan Gao, Bing-Hui Zhao, Qian-Yu Li, Wen-Jing Zhu, Ping Xu and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jin-Guo Liu *Department of Oncology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Lin Yu *Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Xian-Ling Guo *Department of Oncology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Xue-Min HeDepartment of Oncology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Man LiDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Ren-Yuan GaoDepartment of Abdominal Surgery, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Bing-Hui ZhaoDepartment of Radiology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Qian-Yu LiDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Wen-Jing ZhuDepartment of Orthopedics, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Ping XuStandard BioTools, Shanghai, China.
Xiao-Hua GuDepartment of Interventional Therapy, Zhongshan Hospital, Fudan University, Shanghai, China.
Yong-An ChenDepartment of Oncology, No. 455 Hospital of Chinese People's Liberation Army, The Navy Medical University, Shanghai, China.
Xiao-Lan YinDepartment of Oncology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Yan ShangDepartment of Respiratory and Critical Care Medicine, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Zhen-Hong GuoNational Key Laboratory of Medical Immunology & Institute of Immunology, Naval Medical University, Shanghai, China.
Jia-Hao MaoCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Yang-Xi HuCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Li-Ming LuCentral Laboratory, Shanghai Chest Hospital and Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jian HuaSPH Biotherapeutics (Shanghai) Limited, Cellular Therapeutics Center for Cancers, Shanghai, China.
Hua ZhangSPH Biotherapeutics (Shanghai) Limited, Cellular Therapeutics Center for Cancers, Shanghai, China.
Yue Li *SPH Biotherapeutics (Shanghai) Limited, Cellular Therapeutics Center for Cancers, Shanghai, China. yueli7@126.com.ORCID 0009-0009-4953-4939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-Infiltrating Lymphocytes (TILs) immunotherapy is a highly promising treatment for Non-small Cell Lung Cancer (NSCLC), which is responsible for 18% of all cancer-related deaths. The heterogeneity of TILs remains poorly understood. Here, we utilized combined single-cell RNA (scRNA)/T cell receptor sequencing (scTCR-seq) data from lung adenocarcinoma (LUAD) patients. Naïve CD4

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsLymphocytes, Tumor-InfiltratingCD8-Positive T-LymphocytesHumans

Identifiers

PMID40325180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.